Nutrient restriction and radiation therapy for cancer treatment: When less is more

Oncologist

Volumn 18, Issue 1, 2013, Pages 97-103

  Champ, Colin E ^a   Baserga, Renato ^a   Mishra, Mark V ^a   Jin, Lianjin ^a   Sotgia, Federica ^a   Lisanti, Michael P ^a   Pestell, Richard G ^a   Dicker, Adam P ^a   Simone, Nicole L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Calorie restriction; Cancer; Intermittent fasting; Radiotherapy

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN RECEPTOR SUBSTRATE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN RECEPTOR;

APOPTOSIS; ARTICLE; CALORIC RESTRICTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; DISEASE CONTROL; EVIDENCE BASED PRACTICE; HUMAN; MORTALITY; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

CALORIC RESTRICTION; CLINICAL TRIALS AS TOPIC; EATING; ENERGY INTAKE; HUMANS; LONGEVITY; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS;

EID: 84873037371     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0164     Document Type: Article

References (91)

1. Longo VD, Fontana L. Calorie restriction and cancer prevention: Metabolic and molecular mechanisms. Trends Pharmacol Sci 2010; 31: 89-98.
2. Hursting SD, Kari FW. The anti-carcinogenic effects of dietary restriction: Mechanisms and future directions. Mutat Res 1999; 443: 235-249.
3. Hursting SD, Lavigne JA, Berrigan D et al. Calorie restriction, aging, and cancer prevention: Mechanisms of action and applicability to humans. Annu Rev Med 2003; 54: 131-152.
4. Rous P. The influence of diet on transplanted and spontaneous mouse tumors. J Exp Med 1914; 20: 433-451.
5. Rous P. The rate of tumor growth in underfed hosts. Proc Soc Exp Biol Med 1911; 8: 128-130.
6. Tannenbaum A. Effects of varying caloric intake upon tumor incidence and tumor growth. Ann N Y Acad Sci 1947; 49: 5-17.
7. Bischoff F, Long ML, Maxwell LC. Influence of caloric intake upon the growth of sarcoma. Am J Cancer 1935; 180: 549.
8. De Lorenzo MS, Baljinnyam E, Vatner DE et al. Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis 2011; 32: 1381-1387.
9. Mukherjee P, El-Abbadi MM, Kasperzyk JL et al. Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br J Cancer 2002; 86: 1615-1621.
10. Dunn SE, Kari FW, French Jet al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 57: 4667-4672.
11. Berrigan D, Perkins SN, Haines DC et al. Adultonset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. Carcinogenesis 2002; 23: 817-822.
12. Cheney KE, Liu RK, Smith GS et al. The effect of dietary restriction of varying duration on survival, tumor patterns, immune function, and body temperature in B10C3F1 female mice. J Gerontol 1983; 38: 420-430.
13. Ross MH, Bras G. Lasting influence of early caloric restriction on prevalence of neoplasms in the rat. J Natl Cancer Inst 1971; 47: 1095-1113.
14. Nolen GA. Effect of various restricted dietary regimens on the growth, health and longevity of albino rats. J Nutr 1972; 102: 1477-1493.
15. Michels KB, Ekbom A. Caloric restriction and incidence of breast cancer. JAMA 2004; 291: 1226-1230.
16. Mellemkjaer L, Emborg C, Gridley G et al. Anorexia nervosa and cancer risk. Cancer Causes Control 2001; 12: 173-177.
17. Adams TD, Stroup AM, Gress RE et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 2009; 17: 796-802.
18. Brolin RL, Robertson LB, Kenler HA et al. Weight loss and dietary intake after vertical banded gastroplasty and Roux-en-Y gastric bypass. Ann Surg 1994; 220: 782-790.
19. Dias MC, Ribeiro AG, Scabim VM et al. Dietary intake of female bariatric patients after anti-obesity gastroplasty. Clinics (Sao Paulo) 2006; 61: 93-98.
20. Trostler N, Mann A, Zilberbush N et al. Weight loss and food intake 18 months following vertical banded gastroplasty or gastric bypass for severe obesity. Obes Surg 1995; 5: 39-51.
21. Kagawa Y. Impact of Westernizationonthe nutrition of Japanese: Changes in physique, cancer, longevity and centenarians. Prev Med 1978; 7: 205-217.
22. Hite AH, Berkowitz VG, Berkowitz K. Low-carbohydrate diet review: Shifting the paradigm. Nutr Clin Pract 2011; 26: 300-308.
23. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 2003; 348: 1625-1638.
24. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistanceandtype2 diabetes. Nature 2006; 444: 840-846.
25. Kroenke CH, Chen WY, Rosner B et al. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 2005; 23: 1370-1378.
26. Ligibel J. Obesity and breast cancer. Oncology (Williston Park) 2011; 25: 994-1000.
27. Zhu Z, Jiang W, Thompson HJ. Effect of energy restriction on tissue size regulation during chemically induced mammary carcinogenesis. Carcinogenesis 1999; 20: 1721-1726.
28. Lok E, Scott FW, Mongeau R et al. Calorie restriction and cellular proliferation in various tissues of the female Swiss Webster mouse. Cancer Lett 1990; 51: 67-73.
29. Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B et al. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci U S A 1994; 91: 9995-9999.
30. James SJ, Muskhelishvili L. Rates of apoptosis and proliferation vary with caloric intake and may influence incidence of spontaneous hepatoma in C57BL/6 x C3H F1 mice. Cancer Res 1994; 54: 5508-5510.
31. Raffaghello L, Lee C, Safdie FM et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A 2008; 105: 8215-8220.
32. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992; 65: 311-320.
33. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008; 12: 589-603.
34. Creighton CJ, Casa A, Lazard Z et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008; 26: 4078-4085.
35. Taunk NK, Goyal S, Moran MS et al. Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol 2010; 96: 204-208.
36. Resnicoff M, Coppola D, Sell C et al. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 1994; 54: 4848-4850.
37. Papa V, Pezzino V, Costantino A et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990; 86: 1503-1510.
38. Peyrat JP, Bonneterre J, Hecquet B et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993; 29A: 492-497.
39. Baserga R. The contradictions of the insulinlike growth factor 1 receptor. Oncogene 2000; 19: 5574-5581.
40. Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 1995; 73: 311-331.
41. Bonneterre J, Peyrat JP, Beuscart R et al. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 1990; 50: 6931-6935.
42. Adélaïde J, Finetti P, Bekhouche I et al. Integrated profiling of basal and luminal breast cancers. Cancer Res 2007; 67: 11565-11575.
43. Turner BC, Haffty BG, Narayanan L et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57: 3079-3083.
44. Railo MJ, von Smitten K, Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 1994; 30A: 307-311.
45. Perer ES, Madan AK, Shurin A et al. Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res 2000; 94: 1-5.
46. Ruggeri BA, Klurfeld DM, Kritchevsky D et al. Caloric restriction and 7, 12-dimethylbenz (a) anthracene-induced mammary tumor growth in rats: Alterations in circulating insulin, insulin-like growth factors Iand II, andepidermal growth factor. Cancer Res 1989; 49: 4130-4134.
47. Muñoz MT, Argente J. Anorexia nervosa in female adolescents: Endocrine and bone mineral density disturbances. Eur J Endocrinol Sep 2002; 147: 275-286.
48. Dunn SE, Hardman RA, Kari FW et al. Insulinlike growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosisinducedbydiverse anticancer drugs. Cancer Res 1997; 57: 2687-2693.
49. Cosaceanu D, Budiu RA, Carapancea M et al. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 2007; 26: 2423-2434.
50. Wen B, Deutsch E, Marangoni E et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 2001; 85: 2017-2021.
51. Lee C, Safdie FM, Raffaghello L et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res 2010; 70: 1564-1572.
52. Clemmons DR, Underwood LE. Nutritional regulation of IGF-I and IGF binding proteins. Ann Rev Nutr 1991; 11: 393-412.
53. Barger JL, Kayo T, Vann JM et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008; 3: e2264.
54. Baserga R. The insulin receptor substrate-1: A biomarker for cancer? Exp Cell Res 2009; 315: 727-732.
55. Fresno Vara JA, Casado E, de Castro J et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
56. Guppy A, Jamal-Hanjani M, Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol 2011; 7: 727-736.
57. Ouyang P, Jiang Y, Doan HM et al. Weight loss via exercise with controlled dietary intake may affect phospholipid profile for cancer prevention in murine skin tissues. Cancer Prev Res (Phila) 2010; 3: 466-477.
58. Kandel ES, Skeen J, Majewski N et al. Activation of Akt/protein kinase B overcomes a G (2) /m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 2002; 22: 7831-7841.
59. Price BD, Youmell MB. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res 1996; 56: 246-250.
60. Söderlund K, Pérez-Tenorio G, Stal O. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells. Int J Oncol 2005; 26: 25-32.
61. Cataldi A, Zauli G, Di Pietro R et al. Involvement of the pathway phosphatidylinositol-3-kinase/ AKT-1 in the establishment of the survival response to ionizing radiation. Cell Signal 2001; 13: 369-375.
62. Gupta AK, Cerniglia GJ, Mick R et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 2003; 56: 846-853.
63. Jiang W, Zhu Z, Thompson HJ. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res 2008; 68: 5492-5499.
64. Lin K, Hsin H, Libina N et al. Regulation of the Caenorhabditis elegans longevity protein DAF-16 by insulin/IGF-1 and germline signaling. Nat Genet 2001; 28: 139-145.
65. Shaw RJ, Cantley LC. Ras, PI (3) K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-430.
66. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
67. Moore T, Beltran L, Carbajal S et al. Dietary energy balance modulates signaling through the Akt/ mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res (Phila) 2008; 1: 65-76.
68. Lashinger LM, Malone LM, Brown GW et al. Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer. Cancer Prev Res (Phila) 2011; 4: 1041-1051.
69. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-575.
70. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009; 89: 1025-1078.
71. Zannella VE, Cojocari D, Hilgendorf S et al. AMPK regulates metabolism and survival in response to ionizing radiation. Radiother Oncol 2011; 99: 293-299.
72. He Q, Gao Z, Yin J et al. Regulation of HIF-1' activity in adipose tissue by obesity-associated factors: Adipogenesis, insulin, and hypoxia. Am J Physiol Endocrinol Metab 2011; 300: E877-E885.
73. Mazzoletti M, Bortolin F, Brunelli L et al. Combination of PI3K/mTOR inhibitors: Antitumor activity and molecular correlates. Cancer Res 2011; 71: 4573-4584.
74. Shaw LM. The insulin receptor substrate (IRS) proteins: At the intersection of metabolism and cancer. Cell Cycle 2011; 10: 1750-1756.
75. Sanli T, Rashid A, Liu C et al. Ionizing radiation activates AMP-activated kinase (AMPK): A target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 2010; 78: 221-229.
76. Slichenmyer WJ, Nelson WG, Slebos RJ et al. Loss of a p53-associated G1checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993; 53: 4164-4168.
77. Green AS, Chapuis N, Maciel TT et al. The LKB1/ AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010; 116: 4262-4273.
78. Goodwin PJ, Stambolic V, Lemieux J et al. Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011; 126: 215-220.
79. Kalm LM, Semba RD. They starved so that others be better fed: Remembering Ancel Keys and the Minnesota experiment. J Nutr 2005; 135: 1347-1352.
80. Kelley DE, Wing R, Buonocore C et al. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1287-1293.
81. Heilbronn LK, de Jonge L, Frisard MI et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: A randomized controlled trial. JAMA 2006; 295: 1539-1548.
82. Foster GD, Makris AP, Bailer BA. Behavioral treatment of obesity. Am J Clin Nutr 2005; 82: 230S-235S.
83. Reed MJ, Penn PE, Li Y et al. Enhanced cell proliferation and biosynthesis mediate improved wound repair in refed, caloric-restricted mice. Mech Ageing Dev 1996; 89: 21-43.
84. Fontana L, Partridge L, Longo VD. Extending healthy life span-from Yeast to humans. Science 2010; 328: 321-326.
85. Lee C, Raffaghello L, Brandhorst S et al. Fasting cycles retardgrowthoftumorsandsensitizearange of cancer cell types to chemotherapy. Sci Transl Med 2012; 4: 124ra127.
86. Evans WK, Nixon DW, Daly JM. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol 1987; 5: 113-124.
87. Fox KM, Brooks JM, Gandra SR et al. Estimation of Cachexia among Cancer Patients Based on Four Definitions. J Oncol 2009; 2009: 693458.
88. Demark-Wahnefried W, Rimer BK, Winer EP. Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 1997; 97: 519-526, 529; quiz 527-528.
89. Safdie FM, Dorff T, Quinn D et al. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY) 2009; 1: 988-1007.
90. Raffaghello L, Safdie F, Bianchi G et al. Fasting and differential chemotherapy protection in patients. Cell Cycle 2010; 9: 4474-4476.
91. Mukherjee P, Sotnikov AV, Mangian HJ, et al. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 1999; 91: 512-523.